Amylyx Pharmaceuticals to sell 14M common shares under underwriting agreement
Amylyx Pharmaceuticals entered an underwriting agreement to sell up to 16,203,500 shares of common stock to Leerink Partners, Morgan Stanley & Co., and others. The transaction indicates planned capital raising activity to bolster the company's financial position.
View filing at SEC.gov →